<DOC>
	<DOCNO>NCT02446340</DOCNO>
	<brief_summary>The purpose study examine safety outcome healthy volunteer systemic administration multiple ascend dos dalazatide .</brief_summary>
	<brief_title>Multiple Ascending Dose Safety Study ShK-186 ( Dalazatide ) Healthy Volunteers</brief_title>
	<detailed_description>The purpose study examine safety outcome healthy volunteer systemic administration multiple ascend dos dalazatide deliver via subcutaneous injection twice per week total 9 dos .</detailed_description>
	<criteria>1. healthy normal male female subject , age 18 45 , inclusive ; 2. able communicate able provide valid , write informed consent ; 3. within body mass index ( BMI ) range approximately 18.0 30.0 kg/m2 , inclusive ; 4. minimum weight 50 kg ; 5. willingness remain totally abstinent use adequate contraception ; e.g. , 2 follow method : hormonal contraceptive , intrauterine device , condom , diaphragm , spermicidal gel/foam ) order prevent pregnancy screen visit 60 day followup visit . For men , donation sperm period also prohibit . 1. presence clinically significant medical history determine investigator . 2. history clinically significant cardiac abnormality presence clinically significant abnormality 12lead ECG . 3. history preexist paresthesia neuropathy ; 4. abnormality neurologic exam screen baseline 5. history cancer require systemic chemotherapy radiation ; individual history nonmelanoma skin cancer , nonrecurring carcinoma situ treat laser cryotherapy cervical cancerinsitu , resect surgically evidence disease , may accept case case basis discretion Investigator ; 6. presence acute infection history acute infection within 7 day prior receipt study drug ; additionally , oral temperature may exceed 37.4Â°C baseline ; 7. presence clinically significant laboratory abnormality ( chemistry panel 20 analytes [ Chem20 ; fast 1012 hour ] , complete blood count [ CBC ] , urinalysis [ UA ] ) determine investigator ; 8. positive urine drug screen drug abuse ( opiate , methadone , cocaine , amphetamine , cannabinoids , barbiturate , benzodiazepine , cotinine , tricyclic antidepressant alcohol ) Screening Baseline . 9. typical intake 7 unit alcohol per week ( one unit alcohol equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) 10. positive hepatitis screen ( Hepatitis BsAg antiHCV ) positive Human Immunodeficiency Virus ( HIV ) antibody test ; 11. history multiple drug allergy important view Investigator ; 12. history anaphylaxis history allergy medication , diet , environmental exposure ( include bee sting ) important view Investigator ; 13. participation another clinical trial receipt investigational product within 60 day dose administration ( 5 half life , whichever long ) ; 14. recent ( within 1 year Screening ) history illicit drug use ; 15. history alcohol abuse important view Investigator 16. inadequate venous access would interfere obtain blood sample ; 17. use prescription medication , counter product , herbal remedy nutritional supplement within 7 day study drug administration throughout study , anticipate need prescription medication prior Study Completion ; 18. recipient blood transfusion transfusion blood plasma product within 60 day study drug administration ; 19. donation blood &gt; 500 mL within 2 month study drug administration ; 20. positive pregnancy test screen baseline ( female subject ) ; 21. history within past 3 month eat disorder condition may lead suspicion participant 's nutritional status ; 22. inability unwillingness comply study restriction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>ShK-186</keyword>
	<keyword>dalazatide</keyword>
	<keyword>Kv1.3</keyword>
	<keyword>SHK</keyword>
</DOC>